Ymm-1

Yttrium (90Y) Citrate is a radioactive pharmaceutical used for intraarticular therapy in joint pain management. This radiopharmaceutical provides localized radiation to synovial tissue. Commonly used in nuclear medicine for targeted treatment. Short half-life ensures rapid clearance from the body.

Yttrium (90Y) Citrate is primarily used to reduce joint inflammation and pain associated with conditions like rheumatoid arthritis. It delivers targeted radiation to the synovium, helping manage symptoms when other treatments are ineffective. This therapy is often considered for patients with persistent synovitis. It is specifically formulated for intraarticular injection to treat localized joint issues.

After administration, Yttrium (90Y) Citrate emits beta radiation that targets inflamed synovial tissue. Patients may experience gradual reduction in joint pain and swelling over several weeks. The treatment aims to provide long-lasting relief by decreasing synovial cell activity. Effects vary by individual response and condition severity.

Handling requires specialized training due to radioactivity; follow radiation safety protocols. Patients should avoid close contact with others for a short period post-treatment. Pregnant or breastfeeding individuals should not receive this therapy. Ensure proper shielding and disposal methods are used during administration.

No direct drug interactions are reported, but caution is advised with other radiation therapies or immunosuppressive drugs. Avoid combining with systemic corticosteroids during treatment. Concomitant use of anti-inflammatory medications may require adjustment. Always disclose all medications to the administering physician.